BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

...Ltd. appointed Thomas Hecht as chairman. He also chairs the boards of Aelix Therapeutics S.L., Vaximm AG...
BioCentury | Sep 28, 2018
Company News

China Medical gets Asian rights to Vaximm's immunotherapy portfolio

...Holdings Ltd. (HKSE:867) gained an exclusive license from Vaximm AG (Basel, Switzerland) to develop and commercialize Vaximm's...
...and royalties. Vaximm declined to disclose financial terms. China Medical did not respond to inquiries. Vaximm...
...treat glioblastoma (see "Vaximm Reports Final Phase I Data for VXM01 in Recurrent Glioblastoma" ). Vaximm AG...
BioCentury | Jun 1, 2018
Clinical News

Vaximm reports final Phase I data for VXM01 in recurrent glioblastoma

...receive single doses of VXM01 every four weeks (see BioCentury Innovations, Oct. 19, 2017) . Vaximm...
...live-attenuated Salmonella typhi vaccine strain Ty21a that carries the VEGF receptor 2 (VEGFR-2; KDR/Flk-1) gene. Vaximm AG...
...MDX-1106 (Compound #), BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) VXM01 American Society of Clinical Oncology Merck KGaA Pfizer Inc. Vaximm AG Vascular...
BioCentury | Apr 23, 2018
Company News

Management tracks: Probiodrug, Alder

...regulation company Exicure Inc. (Skokie, Ill.) hired Matthias Schroff as COO. He was CEO at Vaximm AG...
BioCentury | Oct 20, 2017
Product R&D

Fighting cancer by mouth

...With its first compound through Phase I, Vaximm AG has started to unveil the data and technology...
...can hold up to 300 different epitopes, a key advantage for targeting neoantigens. Last month, Vaximm...
...That's way faster than any other technology I know of." Matthias Schroff, Vaximm Schroff said Vaximm’s...
BioCentury | Jun 1, 2017
Company News

Vaximm combining VXM01 and Bavencio

...trials evaluating its VXM01 in combination with PD-L1 inhibitor Bavencio avelumab from Merck KGaA (Xetra:MRK). Vaximm...
...24, 2014 ). Vaximm AG , Basel, Switzerland Merck KGaA (Xetra:MRK), Darmstadt, Germany Business: Cancer Shannon Lehnbeuter avelumab Bavencio VXM01 Merck KGaA Vaximm AG Vascular...
BioCentury | Sep 9, 2016
Company News

Management tracks

...Oncology company Vaximm AG (Basel, Switzerland) named Matthias Schroff CEO. He was CEO at Mologen AG (Xetra:MGN...
BioCentury | Jul 25, 2016
Clinical News

VXM01: Phase I started

...will have the option to receive VXM01 every 4 weeks for up to 48 weeks. Vaximm AG...
BioCentury | Jun 27, 2016
Clinical News

VXM01: Phase I data

...well tolerated. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Vaximm AG...
BioCentury | May 16, 2016
Clinical News

VXM01: Phase IIa started

...VXM01 the first week followed by single vaccinations every 4 weeks up to week 64. Vaximm AG...
Items per page:
1 - 10 of 15
BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

...Ltd. appointed Thomas Hecht as chairman. He also chairs the boards of Aelix Therapeutics S.L., Vaximm AG...
BioCentury | Sep 28, 2018
Company News

China Medical gets Asian rights to Vaximm's immunotherapy portfolio

...Holdings Ltd. (HKSE:867) gained an exclusive license from Vaximm AG (Basel, Switzerland) to develop and commercialize Vaximm's...
...and royalties. Vaximm declined to disclose financial terms. China Medical did not respond to inquiries. Vaximm...
...treat glioblastoma (see "Vaximm Reports Final Phase I Data for VXM01 in Recurrent Glioblastoma" ). Vaximm AG...
BioCentury | Jun 1, 2018
Clinical News

Vaximm reports final Phase I data for VXM01 in recurrent glioblastoma

...receive single doses of VXM01 every four weeks (see BioCentury Innovations, Oct. 19, 2017) . Vaximm...
...live-attenuated Salmonella typhi vaccine strain Ty21a that carries the VEGF receptor 2 (VEGFR-2; KDR/Flk-1) gene. Vaximm AG...
...MDX-1106 (Compound #), BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) VXM01 American Society of Clinical Oncology Merck KGaA Pfizer Inc. Vaximm AG Vascular...
BioCentury | Apr 23, 2018
Company News

Management tracks: Probiodrug, Alder

...regulation company Exicure Inc. (Skokie, Ill.) hired Matthias Schroff as COO. He was CEO at Vaximm AG...
BioCentury | Oct 20, 2017
Product R&D

Fighting cancer by mouth

...With its first compound through Phase I, Vaximm AG has started to unveil the data and technology...
...can hold up to 300 different epitopes, a key advantage for targeting neoantigens. Last month, Vaximm...
...That's way faster than any other technology I know of." Matthias Schroff, Vaximm Schroff said Vaximm’s...
BioCentury | Jun 1, 2017
Company News

Vaximm combining VXM01 and Bavencio

...trials evaluating its VXM01 in combination with PD-L1 inhibitor Bavencio avelumab from Merck KGaA (Xetra:MRK). Vaximm...
...24, 2014 ). Vaximm AG , Basel, Switzerland Merck KGaA (Xetra:MRK), Darmstadt, Germany Business: Cancer Shannon Lehnbeuter avelumab Bavencio VXM01 Merck KGaA Vaximm AG Vascular...
BioCentury | Sep 9, 2016
Company News

Management tracks

...Oncology company Vaximm AG (Basel, Switzerland) named Matthias Schroff CEO. He was CEO at Mologen AG (Xetra:MGN...
BioCentury | Jul 25, 2016
Clinical News

VXM01: Phase I started

...will have the option to receive VXM01 every 4 weeks for up to 48 weeks. Vaximm AG...
BioCentury | Jun 27, 2016
Clinical News

VXM01: Phase I data

...well tolerated. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Vaximm AG...
BioCentury | May 16, 2016
Clinical News

VXM01: Phase IIa started

...VXM01 the first week followed by single vaccinations every 4 weeks up to week 64. Vaximm AG...
Items per page:
1 - 10 of 15